Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis
Clinical Rheumatology, pp 1–9, First Online: 15 August 2017
Wai Chung Yong, Anawin Sanguankeo, Sikarin Upala
Only rarely do Vitamin D meta-analyses consider differences in dose sizes
This study found only a 0.5 reduction in pain - on a scale of 0-10
Not a surprise when the Vitamin D dose size was ignored
- Fibromyalgia treated with Vitamin D (50,000 IU weekly for 3 months) – 2016, 2017, 2018, 2019
- 400,000 IU of vitamin D reduced adult pain and improved quality of life – March 2014
- Fibromyalgia pain reduced with vitamin D intervention that achieved 30-48 ng – RCT Feb 2014
- Overview Fibromyalgia or Chronic Fatigue and vitamin D
Pain - chronic category has the following
See also
- Overview Pain and Vitamin D
- Percentage of people with pain increased 25 percent in 18 years – Jan 2019
- Pain not reduced by 60,000 IU monthly vitamin D (need 50,000 IU weekly) – RCT Aug 2023
- Overview Fibromyalgia or Chronic Fatigue and vitamin D
- Overview Rheumatoid Arthritis and vitamin D
- Shingles and vitamin D
- Shin splints decrease with vitamin D
- Migraine and Vitamin D
- Headache category
82 items - "musculoskeletal pain" 490 items as of Aug 2023
- "chronic fatigue" 185 items as of Jan 2017
- Category Back Pain
44 items - 7 pain studies in VitaminDWiki with KNEE in the title as of Aug 2023 (see below)
- Opioid OR Opiate OR Morphine in the title 10 pages as of June 2021
Chronic non-specific widespread pain (CWP) including fibromyalgia (FMS) is characterized by widespread pain, reduced pain threshold, and multiple tender points on examination, causing disability and decreased quality of life. Vitamin D has been proposed as an associated factor in CWP. This meta-analysis aimed to explore the benefit of vitamin D supplementation in the management of CWP. A comprehensive search of the CENTRAL, MEDLINE, and Embase databases was performed from inception through January 2017. The inclusion criterion was the randomized clinical trials’ evaluating the effects of vitamin D treatment in adult subjects with CWP or FMS. CWP was defined as chronic recurrent musculoskeletal pain without secondary causes; FMS patients met the American College of Rheumatology criteria for FMS. Study outcome was assessed using visual analog scale (VAS) of pain intensity. Pooled mean difference (MD) of VAS and 95% confidence interval (CI) were calculated using a random-effect meta-analysis. Meta-regression analysis using a random-effects model was performed to explore the effects of change in vitamin D in the treatment group on difference in the mean of VAS. Sensitivity analysis was performed to evaluate the robustness of results. The between-study heterogeneity of effect size was quantified using the Q statistic and I2.Data were extracted from four randomized controlled trials involving 287 subjects. Pooled result demonstrated a significantly lower VAS in CWP patients who received vitamin D treatment compared with those who received placebo (MD = 0.46; 95% CI 0.09–0.89, I2 = 48%).
Meta-regression analysis revealed no significant relationship between the changes of vitamin D and VAS (coefficient = 0.04 (95% CI −0.01 to 0.08), p = 0.10). In this meta-analysis, we conclude that vitamin D supplementation is able to decrease pain scores and improve pain despite no significant change in VAS after increasing serum vitamin D level. Further studies need to be conducted in order to explore the improvement of functional status, quality of life, and the pathophysiological change that improves chronic widespread pain.
Publisher wants $40 for the PDF
Printer Friendly Follow this page for updates8699 visitors, last modified 17 Aug, 2017,